GPT and non-small cell lung carcinoma: Promising early phase clinical results with intravenous and subcutaneous ALT-803 administration have been also reported in allogeneic hematopoietic cell transplantation, non-small cell lung cancer, melanoma, renal cell carcinoma and head and neck cancers, suggesting that systemic ALT-803 may have a therapeutic effect on NMIBC [9–11].